"A startup can be just as big a success as a Leibniz Prize!"
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
Mass spectrometry imaging provides new insights into X-linked hypophosphatemia
The renal phosphate wasting disease X-linked hypophosphatemia (XLH) is a rare metabolic disorder of the bones associated with severe renal phosphate loss. The first symptoms of the genetic defect appear in childhood and adolescence and can…
From Lab to Therapy: Broermann Award Recognizes Obesity and Diabetes Research at Helmholtz Munich
Prof. Matthias Tschöp, former CEO and Scientific Director of Helmholtz Munich and founding director of the Institute for Diabetes and Obesity, will receive the Broermann Medical Innovation Award 2026. The award recognizes his research at Helmholtz…
Timo Müller Recognized as a Highly Cited Researcher 2026
Prof. Timo Müller, Director of the Institute for Diabetes and Obesity at Helmholtz Munich, has been named a Highly Cited Researcher 2026 by Clarivate. This international recognition honors researchers whose scientific publications are highly cited…
Boosting research into post-infectious diseases: Helmholtz Munich coordinates new NAKO data resource
Helmholtz Munich is coordinating NAKO-PAIS, a project to expand the database of the German National Cohort (NAKO) for research into post-infectious diseases such as Long COVID and ME/CFS. The Federal Ministry of Research, Technology and Space (BMFTR)…